Oncogramme Personalized Medicine
“One patient, one tumor, one treatment…” is Oncomedics’ philosophy, based on special care for each patient. This means that each individual needs her/his own customized anticancer treatment. Currently, treatment selection process is empirical and rests on the “most efficient on the greatest number” principle, with some adaptations according performance status and genetic data when available. Effectiveness of such procedure is significantly constrained by intrinsic tumor resistances, unknown before treatment, as well as variable severity of its side effects.
Based on the idea of the antibiogram, the Oncogramme aims at helping physicians select the most appropriate cure for a cancer patient, by providing additional information on sensitivity and resistance of her/his cancer to molecules of routine use in the clinical setting.
These characteristics are identified by assessing, through a cancer-specific in vitro functional assay, responses of a patient’s qualified tumor fragment to various anticancer drugs. Optimal therapies, but also those that will be inefficient, are then identified thanks to the profiles obtained. This information is included in the patient’s medical file to subsequently assist the clinical team in charge of prescribing the most suitable regimen.
Oncomedics has completed the experimental step of a pilot clinical trial focusing on stage-IV colorectal cancer patients evaluating the predictive capacities of the Oncogramme. Results are currently undergoing a thorough analysis and will be published very soon to demonstrate the power of this technology.
Ultimately, Oncomedics’ Oncogramme will be available to colorectal cancer patients as a ready-to-use assay, under the close assistance of their physicians, to improve effectiveness of treatments, outcome of cancer and patients’ quality of life.
How to request an Oncogramme:
Oncomedics cannot directly interact with colorectal cancer patients because of physician-patient privilege. Patients should thus ask her/his physician to contact Oncomedics before surgery so that a fresh (unfixed) fragment of her/is tumor is reserved by the pathologist in charge of diagnosis. A conservation tube will be sent to the pathology laboratory prior to surgery for this tumor fragment to be selected, and the sample will be sent back to Oncomedics’ facility where the functional analysis will be performed. Results will be made available to the physician for insertion in the decisional process.